Navigation Links
aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
Date:7/14/2014

SAN DIEGO, July 14, 2014 /PRNewswire/ -- aTyr Pharma, an innovative rare disease therapeutics enterprise announced today, the scientific publication of a splice variant of a tRNA synthetase in association with a rare muscle disease.  This article, published in the Journal of Biological Chemistry, demonstrated novel findings relative to Physiocrine proteins, that include extracellular functions derived from the tRNA synthetase gene family.  These data further highlight the potential role of Physiocrine splice variants in muscle physiology.  The data is consistent with the discovered splice variant being a target of auto-antibodies in a rare muscle disease.

"This is an important milestone in our journey towards understanding the role that physiocrines, like those described in this paper, play in regulating tissue homeostasis in normal tissues and in diseased states," said John Mendlein, Ph.D., CEO and executive chairman of aTyr Pharma. 

About Physiocrines
Among their various homeostatic functions, some Physiocrines act as extracellular signaling molecules to orchestrate immuno-homeostasis in response to stress and other physiological changes. Physiocrines comprise naturally occurring proteins derived from tRNA synthetases that play fundamental roles in the function of human physiology and restoring pathophysiological states to a healthier state. aTyr is currently focused on Physiocrines that act as endogenous modulators of our immune and regenerative systems. Physiocrines offer the opportunity for modulating biological pathways through newly discovered naturally occurring mechanisms, many of which may provide multiple therapeutic advantages, including improved efficacy and reduced side effect profiles compared to many existing therapeutics.

About aTyr Pharma
aTyr Pharma is developing  a pipeline of therapeutic products based on Physiocrine biology. To protect these products aTyr built a dominant intellectual property estate comprising over 200 patent applications and patents. aTyr's key programs are currently focused on rare disorders where the immune system is imbalanced. These diseases are serious potentially life threatening autoimmune conditions, for which there are currently no effective, safe, long term treatments. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Partners. For more information, please visit http://www.atyrpharma.com.

Media Contact:
Holly Chrzanowski
hchrzanowski@atyrpharma.com
+1.619.742.4452

Logo - http://photos.prnewswire.com/prnh/20120809/MM55538LOGO


'/>"/>
SOURCE aTyr Pharma
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  Marking its ... accessible breast and ovarian cancer risk test, ... analyzing 30 genes that highly impact the most ... Available today, the Color Test analyzes hereditary cancer ... stomach, and uterine cancers. The Color Test is ...
(Date:4/28/2016)... 28, 2016  The blood testing market in ... to Kalorama Information and The Freedonia Group in a ... acid testing.  The healthcare research firm said that ... blood collection stations and in improving testing at the ... report, Blood Testing Market in China ...
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... ... Journal, patients report dissatisfaction with numerous issues related to medical care in the ... billing, and poor bedside manner from hospital staff. Commenting on this article, the ...
(Date:5/3/2016)... ... ... In April, Amerec launched a new website designed with optimal user experience ... and sauna solutions. , First, the Amerec website has been redesigned to be easier ... site’s features, especially the Steam Builder Tool , to both mobile and desktop ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... presented its 2016 Champion Award to Charles D. Pulido, R.Ph., Co-Founder of NCPDP ... Pharm.D., M.S., Ph.D., Pharmacy Advisor and Health IT Specialist, Office of the National ...
(Date:5/3/2016)... ... 2016 , ... Sue Desmond-Hellmann, chief executive officer of the Bill & Melinda ... human possibility in her keynote address at Georgia State University’s spring commencement ... her rich experience as a scientist, physician and executive, Desmond-Hellmann leads the Gates Foundation’s ...
(Date:5/3/2016)... ... May 03, 2016 , ... Healing Cancer in This Century ... their families move toward recovery and is offered by creator and visionary Carlos Caridad. ... Francis Talk Radio show considering medical and healing modalities of the fields of ...
Breaking Medicine News(10 mins):